Home > Cardiology > ACC 2022 > Heart Failure and Cardiomyopathy > DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia

DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia

Presented By
Prof. Javed Butler, University of Mississippi, MS, USA
ACC 2022
Phase 3, DIAMOND
Heart failure with reduced ejection fraction (HFrEF) patients taking renin-angiotensin-aldosterone system inhibitors (RAASi) had significantly lower serum potassium levels when adding the potassium-binding agent patiromer to their regimen compared with placebo. Prof. Javed Butler (University of Mississippi, MS, USA) presented the initial results from the randomised, phase 3 DIAMOND trial (NCT03888066) [1]. DIAMOND was designed to determine whether patiromer can favourably impact potassium control in patients with HFrEF with hyperkalaemia (>5.5 mEq/L) or a history of hyperkalaemia, and consequently optimise RAASi use to prevent cardiovascular events [2]. Patients with HFrEF and hyperkalaemia were randomised to patiromer (n=439) or placebo (n=439) after an initial run-in phase during which all participants received patiromer. Due to CO...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on